What are the opening hours?

Monday 10am - 6pm Tuesday 7am - 5pm Wednesday 7am - 5pm Thursday 2pm - 10pm Friday 2pm - 10pm Saturday 10am - 5pm Sunday 6pm - 10pm

http://Researcher.O.G/, https://GlobalCannabinoidRC.com/, https://GenevievesDream.com/

The Researcher OG, Santa Barbara, CA (2026)

01/13/2026

"Cannabis unifies people, it brings them together in ways they might not have been otherwise, our cute little family was build on cannabis compassion and love." -Mike Robinson, The Researcher OG CannabisLoveStory.com

01/13/2026

Mood disorders are rarely about a single chemical being “low” or “high.” They are about signaling problems. The ECS, our Master Regulator, is the system that decides how strongly we react, how fast we recover, and whether emotions pass through us or get stuck and erupt. When that system is out of balance, impulsivity, anger, anxiety, and mood instability follow.

THC, CBD, and CBG all interact with this system differently, which is why patients often report benefit when they are used with intention rather than excess. THC primarily engages CB1 receptors, which directly regulate emotional reactivity, threat perception, and stress response. In balanced amounts, THC can reduce hypervigilance and dampen exaggerated emotional spikes, helping someone pause instead of exploding.

When overused, it can do the opposite, which is why balance matters more than dose.

CBD works differently. It does not drive CB1 the way THC does. Instead, it modulates serotonin signaling, reduces excessive glutamate activity, and slows the breakdown of anandamide. This creates emotional buffering without intoxication. Many patients describe this as feeling less reactive rather than sedated, which is critical for mood regulation.

CBG plays a quieter but foundational role. It supports receptor tone, reduces inflammatory signaling, and interacts with adrenergic and serotonergic pathways involved in impulse control. By improving baseline ECS signaling, CBG can help stabilize mood over time rather than just blunt symptoms in the moment.

Research continues to align with these observations. The study “The endocannabinoid system as a target for the treatment of mood disorders,” published in 2014, outlines how restoring ECS balance reduces emotional dysregulation, impulsivity, and exaggerated stress responses.

This is not about being high. It is about restoring signaling integrity so emotions can move through the system without hijacking it. That is ECS balance in action.

-Mike Robinson, The Researcher OG

01/12/2026

"I was gifted with a life that was full of adventure. I've always believed, if you're gifted, that it's incumbent not to think about giving something back." Bob Weir, The Grateful Dead Oct.1947-Jan. 2026

01/12/2026

There's all kinds of Cannabis users - which type are you? Do you like to smoke, ingest, use topicals or a little of all? Do you v**e, dab, or use concentrates - what's you CannaStyle? Let me know in comments.

01/11/2026

It’s pretty simple: when the ECS gets out of balance, sleep is often the first thing that breaks down. Our sleep cycle is driven by a rhythm of neurotransmitters, hormones, and internal feedback loops. When the ECS, our Master Regulator, is underperforming because endocannabinoid tone is low or inflammatory signals are high the brain struggles to shift from wake mode into restorative sleep mode. CBN, CBG, and CBD support sleep by engaging different parts of that regulatory network, helping the body settle into its natural rhythm again.

CBN is often referred to as the “sleep cannabinoid” because it interacts with CB1 receptors and TRPV channels to promote relaxation and sedation. It doesn’t force sleep like a sedative – instead, it helps calm excitatory signals that keep someone keyed up. When TRP channels are tuned down, CBN helps reduce neural noise, allowing the body to transition toward slower brainwave states and deeper sleep cycles. It’s about quieting the chatter; the nervous system needs to shift gears.

CBG works upstream with a broader receptor profile, including CB1 CB2, and alpha-2 adrenergic receptors. These pathways influence alertness and stress signaling. By supporting alpha-2 adrenergic tone, CBG helps reduce the fight-or-flight signals that block the brain’s ability to shift into rest mode. When stress circuitry is modulated, the body can naturally begin releasing sleep-promoting neurotransmitters without artificial suppression.

CBD doesn’t put someone to sleep directly, but it regulates serotonin receptors and FAAH enzyme activity that affect anandamide levels. Elevated anandamide has calming effects on stress and mood circuits and supports the body’s natural transition into sleep. CBD also dampens overactive stress responses by boosting internal endocannabinoid tone, so the sleep-wake cycle isn’t hijacked by excess cortisol or neural excitability. Think of CBD as the stabilizer that keeps the body’s internal timing cues working properly.

Across all three compounds, the mechanism isn’t forcing the body into rest – it’s restoring the internal balance the nervous system needs to regulate sleep naturally. By calming excitatory signaling, reducing stress pathways, and supporting calming neurotransmitters, the body regains its ability to follow its own circadian cues rather than fight them.

Reach out and let’s talk about your ECS Balance.

-Mike Robinson, The Researcher OG

01/11/2026

The ECS, our Master Regulator, is the network in the body that helps regulate mood, appetite, inflammation, sleep, immune responses, metabolism, and stress signals. When someone has low endocannabinoid tone, meaning the body isn’t making enough of its own signaling lipids like anandamide or 2-AG, the system loses responsiveness. That’s clinical endocannabinoid deficiency. Symptoms often look like exaggerated stress responses, inflammation that won’t simmer down, sleep that won’t stabilize, mood that swings harder than the situation calls for, and sensory or digestive signaling that feels out of rhythm.

Phyto-derived cannabinoids like THC, CBD, CBGA, CBG, CBC, and others interact with receptors like CB1 and CB2, as well as enzymes such as FAAH and TRP channels, influencing how long calming signals remain active and how intensely inflammatory or neural irritation signals fire. Think of phyto cannabinoids as support staff for the regulator - they don’t take over, they help the system regain tone.

Then there are the endocannabinoids, the lipids your body makes internally, like anandamide, 2-AG, OEA, and PEA. These are the molecules that act like the body’s own text messages, telling systems when to ramp up and when to calm down. When the ECS is deficient, those messages are either too quiet, too fast, or poorly timed. CBGA, the raw plant precursor, has shown influence upstream at the enzyme level, shaping internal cannabinoid tone by slowing anandamide breakdown and helping regulatory signaling stay active longer when the body needs calm down the most.

A key study anchoring the relevance of ECS deficiency is”Clinical Endocannabinoid Deficiency (CED) Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, IBS, and More”, (2016), which expanded the deficiency concept beyond speculation and linked it to measurable receptor and enzyme dysfunction across chronic conditions. That was one of the turning points, showing the deficiency theory has real biological legs.

So the takeaway is simple but powerful: when the ECS lacks tone, phyto cannabinoids help extend the calming lipids, lower the inflammatory noise, and support smoother signaling across systems. The body doesn’t need a lecture; it needs balanced chemistry - the plant simply speaks that language fluently.

Reach out and let’s talk about your ECS Balance.

-Mike Robinson, The Researcher OG

01/11/2026

Epilepsy is a condition characterized by overactive neural firing, chaotic signaling, and an imbalance in the circuits that control excitatory and inhibitory tone. The ECS, our Master Regulator, is woven into that balance by influencing neurotransmitter release, inflammation, and neural excitability. When plant cannabinoids are introduced, they don’t just numb a symptom; they interact with receptor systems that help guide the nervous system back toward equilibrium.

One of the pivotal pieces of clinical research in this space is “Cannabidiol in Patients with Treatment-Resistant Epilepsy”, 2018. In this randomized controlled clinical study, CBD significantly reduced seizure frequency in patients who had not responded to other approaches. That’s not anecdote or buzzword talk - that’s measurable change in neural network behavior driven by modulation of receptor and enzyme activity tied to the ECS and related pathways.

What does this mean in practical terms? Plant cannabinoids influence how neurons talk to each other. CBD indirectly affects GABA and glutamate balance by engaging multiple receptors and signaling systems, including 5-HT1A and TRP channels, which, in turn, calm excitatory networks. This modulation doesn’t “turn off the brain” - it adjusts malfunctioning feedback loops so seizures occur less often. CBGA, being upstream in the biosynthetic pathway, also influences enzyme activity and receptor modulation that feed into anandamide and 2-AG levels, which are central to inhibitory tone.

Over time, the brain adapts to this modulation through receptor expression changes and network rewiring. That’s why some patients report not only reduced seizure frequency but improved baseline stability in mood, sleep, and stress responses. The body is not ignoring its own systems - it’s learning to regulate again.

Cannabis-derived cannabinoids aren’t curing epilepsy with mystique - they are engaging biological circuits tied to neural stability. Studies like this show that controlled clinical work supports real shifts in seizure patterns, not speculation.

Let me know if you’d like more information. I have Epilepsy and use cannabinoids.

-Mike Robinson, The Researcher OG

01/11/2026

The concept of endocannabinoid deficiency isn’t fringe; it’s rooted in the understanding that the ECS, our Master Regulator, maintains equilibrium across stress, mood, pain, inflammation, digestion, and more. When someone’s endocannabinoid tone stays consistently low, or the enzymes that make and break anandamide and 2-AG misfire, the body struggles to stabilize signals. That’s what we call clinical endocannabinoid deficiency.

Clinical research like “Endocannabinoid Deficiency Syndrome: A Possible Trigger of Migraine, Fibromyalgia, Irritable Bowel Syndrome” (2004) suggested that low levels of endocannabinoids could underlie conditions defined by chronic pain, stress, and regulatory instability. Over time, this idea has expanded into how ECS imbalance shows up as stress dysregulation, mood swings, pain amplification, and disrupted sleep.

Cannabis derived cannabinoids like CBD and CBGA don’t replace the ECS; they help guide it back toward balance. Phytocannabinoids interact with receptors and enzymes that influence endocannabinoid tone. CBD inhibits FAAH, the enzyme that breaks down anandamide, so anandamide stays around longer and calms stress circuits rather than exiting too quickly.

CBGA interacts with TRP channels and PPAR receptors that influence inflammation and nerve signaling. Together, this helps reduce the intensity of pain signals and support emotional regulation. This upregulation helps our balance.

THC and its downregulation help our body when under chronic stress, as the ECS becomes out of balance. Cannabinoids from the plant provide external support that nudges enzyme activity and receptor signaling back into a more regulated range. That’s not about high effects or intoxication, it’s about biochemical modulation to help the body feel more balanced.

This is real science, not buzz. Studies continue to characterize deficiency states and the ways in which phytocannabinoids complement our internal systems, such as when CBD blocks the action of FAAH, the enzyme responsible for breaking down cannabinoids in our bodies and the plant faster than we’d like.

Cannabis based support can create a buffer while the ECS regains its capacity to self-regulate. That’s why consumers and clinicians alike are watching this space with grounded interest instead of myth.

Let’s talk and see how I can help you.

-Mike Robinson, The Researcher OG

01/10/2026

When someone is trying to reduce tolerance due to long-term THC use or other substance stress hits the ECS, our Master Regulator works hard because it controls mood, stress, sleep, inflammation, and pain signals. Chronic use rewires enzyme activity, alters endocannabinoid levels, and disrupts the system's balance. That’s where CBGA enters the frame, not as a quick fix or buzzword but as an upstream modulator that influences how cannabinoids interact with receptors and enzymes that drive balance control.

CBGA sits at the biochemical root of the cannabinoid pathway and plays a role in endocannabinoid tone by feeding into the production of downstream cannabinoids and supporting enzyme pathways like FAAH that regulate anandamide and 2-AG levels. When anandamide and 2-AG stabilize mood circuits, and calming neurotransmitters like GABA get a break from overdrive, withdrawal symptoms like anxiety, unrest, and irritability tend to soften. That’s not speculation; it’s grounded in how these pathways function across multiple preclinical models and biochemical studies.

A key piece of research that helps explain how cannabinoids influence pain and regulatory pathways is “Role of Cannabinoid Receptors and the Endocannabinoid System in Pain”, 2018. This study shows how cannabinoid receptor activity and related channels, such as TRP channels, can modulate pain signaling and inflammatory cascades. These are not the cannabinoid receptors everyone knows about, but they are key regulators of pain perception, inflammation, and nerve signaling that CBGa positively impacts.

By modulating TRP channels, the body can reduce nociceptive signaling and quiet pain intensity. PPAR engagement helps tone down inflammatory cascades that fuel chronic pain states. That means CBGA can support comfort by addressing underlying signals instead of masking symptoms.

The science around CBGA is still expanding, but what we see over and over is that upstream regulators shift the internal landscape rather than just pushing receptors. For someone dealing with withdrawal-related stress or chronic pain, CBGA offers a mechanism rooted in balance and signal modulation. That’s real science backing real effects, not guesses.

If you want precise study titles and citations related to TRP, PPAR, and endocannabinoid enzymatic pathways, with year only, I can drop that next.

-Mike Robinson, The Researcher OG

01/10/2026

The ECS, our Master Regulator, is built to keep the body in a stable zone - managing mood, sleep, immune tone, pain signaling, appetite, stress perception, and neural communication. It works through endocannabinoids your body makes on its own - like anandamide and 2-AG - which bind to CB1 and CB2 receptors to send balance-setting messages. When a consumer uses THC often or at high doses, THC floods CB1 receptors in the brain repeatedly. The receptors adapt by downregulating - basically pulling some antennas off the roof because the signal is too loud, too often. That’s the first shift in balance: fewer CB1 receptors available means your internal endocannabinoids have fewer places to land.

At the same time, chronic THC exposure can tilt enzyme activity, especially FAAH and MAGL, which break down your internal endocannabinoids. If enzyme tone shifts while receptor numbers are already dipping, your natural modulators clear faster and bind less often. That can feel like increased anxiety, duller mood lift, disrupted sleep onset, heavier insomnia loops, digestive slowdown, stress sensitivity, or the sense that THC “stopped working as it used to.” It didn’t stop; your Master Regulator adapted to survive the overstimulation.

Losing ECS Balance isn’t only about tolerance. It’s about rhythm. The Master Regulator likes variation, pauses, and a mix of signals from multiple phytochemicals, terpenoids, and endogenous modulators. When THC becomes the dominant daily conversation, the ECS loses its multi-system harmony, and the other systems it regulates stop receiving well-timed calibration signals. The day can feel mentally heavier, nights feel longer, sleep feels harder to negotiate, and emotional tone becomes less resilient because the upstream system is no longer setting a steady baseline.

This is why many consumers cycling too much THC eventually feel out of balance even when trying to self-treat serious conditions: dose escalation increases, symptom relief becomes less efficient, anxiety rebounds faster, and the Master Regulator shifts into a defensive adaptation state. The solution isn’t moral judgment, it’s biology: receptors need space to repopulate, enzymes need varied modulation, and endogenous tone needs a chance to rebuild without constant THC occupancy.

Cannabis isn’t the issue. Overstimulation timing is. Too much THC too often without supporting upstream balance leads to receptor scarcity, low endogenous tone, faster endocannabinoid clearance, and a Master Regulator that can’t conduct the orchestra well anymore. When the ECS loses tone, downstream systems destabilize their cadence too.

Keeping THC effective long-term requires letting the Master Regulator breathe, recalibrate, and return to internal equilibrium. That’s the hinge point of the story: when you protect ECS rhythm, you protect ECS tone, and that is where the real north remains - ECS Balance.

Let’s talk and see how I can help you.

-Mike Robinson, The Researcher OG

01/09/2026

Introducing CBGa into my AM routine became the inflection point. CBGA doesn’t directly activate CB1 or CB2 receptors; instead, it acts upstream, influencing enzyme signaling and receptor tone, which can allow CB1 receptors to repopulate and regain sensitivity over time. That biochemical shift matched what I noticed in my own system: the THC oil that had felt muted for months suddenly felt effective again at lower doses. The tolerance wall didn’t vanish instantly, but it softened enough that dosing became more efficient, more predictable, and, finally, worth the effort again.

Lowering tolerance meant I could use less THC while feeling more of the intended effects, getting the most out of the oil without constantly escalating the dose just to reach baseline symptom control. For someone balancing seizures and cancer, that kind of dose efficiency isn’t a luxury; it’s a lifeline. The unexpected twist was that Genevieve’s need for CBGA research didn’t just help her; it recalibrated me. That shift allowed the THC oil to act more meaningfully, especially for sleep and symptom relief, because the receptors were finally in a state to respond again.

What saved me wasn’t a new oil formula; it was restoring receptor tone so the old one could finally work like it was supposed to. Genevieve needed the science, but I needed the alignment, and both pointed to the same truth: when the ECS regains balance, tolerance lowers naturally, endogenous modulators increase, and plant-derived bioactives finally hit their stride again without fighting upstream friction.

That moment in 2016 didn’t just shape a protocol; it validated a principle. If the Master Regulator is out of tune, nothing downstream performs correctly. When it finds its tone, everything else follows suit. Genevieve may have needed CBGA, but the Master Regulator made sure I needed it too, and that shared need rewrote the outcome entirely.

And that’s the quiet revolution of acidic precursors in real time: restoring ECS Balance so the therapies you already trust can finally work at their best again.

-Mike Robinson, The Researcher OG

01/09/2026

Cannabis for dogs isn’t folklore anymore - there’s clinical research showing measurable effects in real canine patients. When veterinary researchers talk about cannabis-derived oils, they mean cannabidiol-focused formulas tested for pain relief, mobility support, stress response, and seizure control.

A key randomized clinical investigation was the “Randomized Blinded Controlled Clinical Trial to Assess the Effect of CBD in Dogs with Osteoarthritis”, 2019, in which dogs treated with CBD oil showed significant reductions in pain scores and improvements in activity levels compared to placebo. That’s controlled data in a real veterinary condition - not guesswork.

Seizures in dogs are another area drawing serious research. In “Randomized Blinded Controlled Trial on CBD for Canine Idiopathic Epilepsy”, 2019, dogs receiving CBD alongside standard anticonvulsants had fewer seizure days and lower overall seizure frequency compared to those on placebo. Here, science quantifies effects, not speculates.

Stress and anxiety are real welfare concerns in dogs. Studies like”Single-Dose CBD Study on Canine Stress and Anxiety,”, 2023, evaluated behavior changes under stress with THC-free CBD distillates and found measurable reductions in indicators like whining and restlessness versus placebo. Longitudinal work, such as the 2024 Longer-Term CBD Stress Response Investigation, extended this by showing that repeated daily dosing lowered stress markers during car travel tests over weeks compared to controls.

Safety is foundational to clinical acceptance. In “Safety Study of Cannabidiol Products in Healthy Dogs” (2024), healthy dogs given broad-spectrum CBD daily for 90 days tolerated treatment well, with minimal adverse events reported and normal clinical labs for most subjects. That’s the kind of safety profile veterinarians need before recommending products.

Taken together, these clinical efforts go well beyond anecdotes. They demonstrate pain modulation, reduced seizure frequency, shifts in stress response, and tolerability patterns in controlled settings with placebo groups and blinded assessments. Cannabis-derived oils for dogs are real, have been studied, and are part of modern veterinary research conversations.

This isn’t about making unsubstantiated claims. It’s about recognizing the depth of inquiry already undertaken and the growing framework vets and caregivers can reference as evidence continues to build. Research evolves, but the science backing canine cannabis oils is real and expanding.

Let’s talk and see how I can help you.

-Mike Robinson, The Researcher OG

The Researcher OG

01/13/2026

01/13/2026

01/12/2026

01/12/2026

01/11/2026

01/11/2026

01/11/2026

01/11/2026

01/10/2026

01/10/2026

01/09/2026

01/09/2026

Address

Opening Hours

Website

Alerts

Shortcuts

Share

Category

Monday	10am - 6pm
Tuesday	7am - 5pm
Wednesday	7am - 5pm
Thursday	2pm - 10pm
Friday	2pm - 10pm
Saturday	10am - 5pm
Sunday	6pm - 10pm